Sedative and antinociceptive effects of different detomidine constant rate infusions, with or without methadone in standing horses by Gozalo Marcilla, Miguel et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sedative and antinociceptive effects of different detomidine
constant rate infusions, with or without methadone in standing
horses
Citation for published version:
Gozalo Marcilla, M, Rodrigues de Oliveira, A, Werneck Fonseca, M, Possebon, FS, Pelligand, L, Taylor, PM
& Luna, SPL 2018, 'Sedative and antinociceptive effects of different detomidine constant rate infusions, with
or without methadone in standing horses', Equine Veterinary Journal. https://doi.org/10.1111/evj.13054
Digital Object Identifier (DOI):
10.1111/evj.13054
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Equine Veterinary Journal
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/evj.13054 
This article is protected by copyright. All rights reserved. 
DR. MIGUEL  GOZALO-MARCILLA (Orcid ID : 0000-0003-1391-0989) 
PROF. FÁBIO SOSSAI POSSEBON (Orcid ID : 0000-0002-0118-6164) 
Article type      : Article 
 
Reference number: EVJ-GA-17-353.R3 
 
Sedative and antinociceptive effects of different detomidine constant rate infusions, with 
or without methadone in standing horses 
 
M. Gozalo-Marcilla1,2, A. Rodrigues de Oliveira1, M. Werneck Fonseca1, F. Sossai 
Possebon1, L. Pelligand3, P. M. Taylor4 and S. P. Loureiro Luna1 
 
1São Paulo State University (UNESP), School of Veterinary Medicine and Animal Science, 
Botucatu, SP, Brazil; 2The Royal (Dick) School of Veterinary Studies and the Roslin 
Institute, The University of Edinburgh, Easter Bush Campus, Midlothian, UK; 3Royal 
Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Hertfordshire, AL9 7TA UK 
and 4Taylor Monroe, Ely, Cambridgeshire, UK.  
 
Running title: Detomidine-methadone infusions in experimental standing horses 
 
Keywords: horse; detomidine; methadone; constant rate infusion; electrical stimulus; thermal 
stimulus; mechanical stimulus 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
*Corresponding author email: miguelgozalomarcilla@gmail.com 
 
Summary 
Background: Standing surgery avoids the risks of general anaesthesia in horses.  
Objectives: To assess sedation, antinociception and gastrointestinal motility in standing 
horses after a detomidine loading dose and 2-hours constant rate intravenous (i.v.) infusion, 
with or without methadone.  
Study design: Blinded, randomised, crossover with seven healthy adult cross-bred horses, 
three geldings and four females (404 ± 22 kg).  
Methods: Five i.v. treatments were administered to all horses with 1-week washout period: 
saline (SAL), detomidine low (2.5 µg/kg bwt + 6.25 µg/kg bwt/h) (DL) and high doses (5 
µg/kg bwt + 12.5 µg/kg bwt/h) (DH) alone or combined with methadone (0.2 mg/kg bwt + 
0.05 mg/kg bwt/h), (DLM) and (DHM), respectively. Height of head above the ground 
(HHAG), electrical (ET), thermal (TT) and mechanical (MT) nociceptive thresholds and 
gastrointestinal motility were evaluated at predetermined times between 5 and 240 minutes. 
A mixed effect model and Kruskal-Wallis test were used to analyse normally and non-
normally distributed data, respectively. 
Results: Sedation (<50% basal HHAG) was achieved for the duration of the infusion, and for 
an additional 15 minutes in DH and DHM groups. Nociceptive thresholds were higher than 
baseline, to the greatest degree and the longest duration, with DHM (ET and TT for 135 
minutes and MT for 150 minutes). After DH, TT was significantly higher than baseline from 
30 to 120 minutes and MT from 15 to 135 minutes. After DLM, ET was increased at 90 
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minutes, TT at 30 minutes and MT for 120 minutes. Gastrointestinal motility was reduced for 
up to 135 minutes after DL, 150 minutes after DLM and 210 minutes after DH and DHM. 
Main limitations: Nociceptive thresholds are not equivalent to surgical stimuli. 
Conclusion: Methadone with the highest detomidine dose (DHM) may provide sufficient 
sedation and analgesia for standing surgical procedures and warrants further investigation. 
 
Introduction 
In equine practice, procedures such as laparoscopy, dentistry, sinus trephination and eye 
enucleations can be performed with the aid of intravenous (i.v.) sedative and analgesic 
constant rate infusions (CRIs) combined with local anaesthesia [1,2]. The aim of using an i.v. 
CRI is to maintain steady plasma drug concentrations, leading to consistent sedation and 
analgesia. Infusions of α2-agonists alone [3-6] or in combination with opioids [4-7] are 
commonly used for this purpose.  
Detomidine CRI has been used under clinical conditions after loading doses of 7.5 – 
15 µg/kg bwt in prospective studies [8-11], and of 7.5 ± 1.87 µg/kg bwt (mean ± s.d.) in a 
retrospective study with 51 horses [12]. These reports describe a variety of protocols with 
mean infusion rates varying from 6.6 to 36 µg/kg bwt/h, with surgery duration of up to 170 
minutes. An in-depth literature review revealed no publications evaluating the effects of 
simultaneous CRIs of detomidine and an opioid such as methadone in standing horses. 
 Based on data from previous experimental studies in standing horses [13], 
pharmacokinetic/pharmacodynamic (PK/PD) modelling [14] was used to simulate the effects 
of different doses and rates of detomidine and methadone on sedation, antinociception and 
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gastrointestinal motility [15]. Leading on from this, we aimed to identify a protocol under 
experimental conditions that provides antinociception without excessive sedation. Loading 
doses of detomidine at 2.5 and 5 µg/kg bwt combined with 0.2 mg/kg bwt methadone 
followed by infusion of detomidine (6.25 or 12.5 µg/kg bwt/h) and methadone (0.05 mg/kg 
bwt/h) were chosen according to the results of simulation [15]. Our hypothesis was that the 
higher doses and infusion rates of detomidine, when combined with methadone would 
produce antinociception with adequate sedation that should be suitable for evaluation under 
clinical conditions.  
 
Materials and methods 
The study was designed as a randomised, placebo-controlled, observer-blinded, crossover 
experiment. Each horse received all treatments with a 1-week washout period between 
treatments. The study was performed during March and April of 2017, at the farm facilities of 
the School of Veterinary Medicine and Animal Science, São Paulo State University 
(UNESP), Botucatu (Brazil) where all the horses were born and lived. Each horse was always 
treated at the same time of day.  
 
Animals 
Seven docile, healthy adult cross-bred horses (three geldings, four mares), 9 – 11 years and 
weighing 372 – 450 kg were enrolled in the study. All had been trained using positive 
reinforcement and used in similar antinociceptive studies. The horses were kept at pasture 
and brought in to covered pens with outdoor access for at least 12 hours, with water ad 
libitum, commercial feed and hay provided until each experiment began. The animals were 
classified as healthy ASA I (American Society of Anesthesiologists) according to physical, 
musculoskeletal and lameness examination, haematology and biochemistry (complete 
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haemogram, blood urea nitrogen, aspartate and alanine transaminases, gamma glutamyl 
transferase and alkaline phosphatase), performed one to 2 weeks before beginning the study. 
No drugs such as sedatives, analgesics, corticosteroids or nonsteroidal anti-inflammatory 
drugs were administered by any route for at least one month prior to the study. 
The sample size was estimated using the sedative [height of head above the ground 
(HHAG)] and antinociceptive (thermal, mechanical and electrical) results of a pilot study and 
data obtained from the same group of horses in previous studies [13,16,17]. Five treatments 
and the differences between means and expected general s.d. 
(https://www.statstodo.com/SSizUnpairedDiff_Pgm.php) (α = 0.05, β = 0.80) were used.  
 
Study design 
On the day of the experiment, each animal was weighed and fly repellent was sprayed onto 
the skin. The hair over the left jugular vein was clipped and the skin disinfected. Thereafter, 1 
ml of 2% lidocaine (Xylestesin 2%)a was injected subcutaneously and one 14-gauge catheter 
(G14 x 70 mm)b was placed for drug administration. 
The hair over the middle third of the dorsal aspect of both metacarpals was clipped for 
placement of the thermal probe (right) and mechanical actuator (left). The hair proximal to 
the coronary band of the left thoracic limb was clipped for placement of the electrodes. A 
strict clipping and cleaning protocol was followed in order to ensure good contact and to 
minimise between-electrode resistance to less than 3 kiloohms (kΩ) [13,18]. 
Each horse was then led to the 6-square metres experimental room, without windows, 
to which fly repellent had been previously applied. A period of thirty minutes was allowed 
for acclimatisation of the horses to the working environment. During this period, two 
adhesive electrodes (2223BRQ)c were placed on the clipped and cleaned area of the left 
coronary band; the electrodes were placed 8 cm from each other and fixed with adhesive 
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strips around the hoof. A commercial horse-blanketd was placed on the back of the horse and 
the thermal (WTT2)d and mechanical (WMT1)d control units, remotely controlled with 
infrared signals, were attached with Velcro. The thermal probe and mechanical actuator were 
attached to the limbs and connected to the control units after the horse had been placed in the 
restraining stocks. A blood pressure cuff (DURA-CUF CRITIKON 17–25 cm)e, positioned at 
the base of the tail, was used to measure heart rate (HR) and systolic arterial blood pressure 
(SAP) with a non-invasive Doppler system (Model 812)f.   
The five treatments were all comprised of a bolus injection followed by a 2-hour CRI, 
assigned using a randomisation websiteg. The treatments were: saline (SAL) (Cloreto de 
sódio 0.9%)h, detomidine (Eqdomin, 10 mg/ml)i low dose (DL, 2.5 µg/kg bwt followed by a 
CRI of 6.25 µg/kg bwt/h), detomidine high dose (DH, 5 µg/kg bwt followed by a CRI of 12.5 
µg/kg bwt/h), detomidine low dose with methadone (Mytedom 10 mg/ml)j (DLM, 2.5 µg/kg 
bwt detomidine + 0.2 mg/kg bwt methadone followed by 2 concurrent CRIs of detomidine 
6.25 µg/kg bwt/h + methadone 0.05 mg/kg bwt/h), and detomidine high dose with methadone 
(DHM, 5 µg/kg bwt detomidine + 0.2 mg/kg bwt methadone followed by 2 concurrent CRIs 
of detomidine 12.5 µg/kg bwt/h + methadone 0.05 mg/kg bwt/h). All bolus doses and 
infusions were diluted with saline by an assistant investigator (M.W.F.) to 10 and 18 ml for 
boluses and infusions, respectively, to keep the main investigator blinded. The CRIs were 
delivered by two calibrated syringe drivers (DigiPump SR8xk and Pilot Anestesial). 
Evaluation of the sedation variables and the responses to noxious stimuli were 
evaluated 3 times before drug administration (T0, baseline values), and once only at T5 (5 
minutes after drug administration), T15, T30, T60, T90, T120, T135, T150, T180, T210 and 
T240. Starting at T15, gastrointestinal motility was scored at the same time points. Evaluation 
of each variable is described in detail elsewhere [13] and summarised briefly below: 
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Sedation  
One investigator (A.R.O.), unaware of treatment group assignment, measured the HHAG to 
determine the degree of sedation [4,5]. Quality of sedation was scored using numerical rating 
scales [13,19] for ataxia and responses to tactile, acoustic and visual stimuli, always in this 
order (Supplementary Item 1).   
 
Nociceptive threshold testing 
Nociceptive stimuli were applied at each time point, always in the same order: electrical, 
thermal and mechanical, immediately after the sedation scoring. All the responses were 
evaluated by the main investigator (M.G.M.), who was unaware of the treatment group 
assignment. Aversive reactions were considered positive responses when the horse lifted its 
foot, pawed the ground, stamped, flexed the limb or walked to avoid the stimulus [20]. 
Further details for electrical, thermal and mechanical threshold testing and devices are 
described elsewhere [13,18,21,22].   
 
Cardiopulmonary variables 
Measured SAP values were corrected by adding the height difference between the right 
atrium of the heart (scapulohumeral joint in the standing horse) and the cuff. A height 
difference of 10.2 cm was considered equivalent to 7.5 mmHg. The respiratory rate (fR) was 
measured by observation of the thoracic movements over 15 seconds. 
 
Abdominal auscultation 
The main investigator (M.G.M.) auscultated the four abdominal quadrants immediately for 
one minute each (right dorsal, right ventral, left dorsal and left ventral), and awarded a 
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motility score, from 0 to 5 according to Boscan et al. [23]. The sum of the scores was 
recorded, ranging from 0 to 20 (0 no motility, 20 maximal motility possible).   
 
Data Analysis  
Normality was evaluated graphically and with normality tests (Shapiro-Wilk) for each 
variable. Descriptive measurements were generated. For parametric variables, a mixed model 
ANOVA with Tukey’s post-hoc test was used to evaluate the differences between treatments 
and time points; data are shown as mean ± s.d. For non-parametric variables, Friedman’s test 
with Dunn’s post-hoc test was used; data are shown as median (range). A significance level 
less than 0.05 was used for all analysis and the calculations were made with the aid of 
Statistical Analysis Softwarem. 
 
Results  
All the horses received all treatments and completed the study.  Appetite and faecal output 
were within normal limits at the end of each session. None of the horses showed signs of 
colic. One horse reacted with mild head-shaking to acoustic and visual stimuli up to T30 
when receiving treatment DLM. No other complications were observed. 
 
Sedation 
Sufficient sedation (<50% of basal HHAG) [5] was achieved for the duration of the infusion 
and for an additional 15 minutes in DH and DHM groups only. Significant differences within 
and between treatments are shown in Figure 1.  
Significant differences within and between treatments for ataxia scores are shown in 
Table 1. With regard to the scores for responses to the different stimuli, few significant 
differences were observed: 1) responses to tactile stimuli had lower scores (diminished 
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response) after DHM compared to SAL at T5 [DHM 1 (0 – 3)] versus [SAL 3 (2 – 3)], T30 
[DHM 0.5 (0 – 2)] versus [SAL 3 (2 – 3)], T60 [DHM 1 (0 – 3)] versus [SAL 3 (2 – 3)] and 
T90 [DHM 1.5 (0 – 3)] versus [SAL 3 (1 – 3)]; and 2) responses to visual stimuli had lower 
scores (diminished response) than baseline [2 (1 – 3)] for treatment DL at T30 and T60 [0.5 
(0 – 1) at both time points]. Between treatments, scores for visual stimuli were lower after DL 
[0.5 (0 – 1)] than SAL [2 (1 – 2)] at T30. No differences within or between treatments were 
observed for acoustic stimuli. 
 
Nociceptive threshold testing 
Differences within and between treatments are shown in Figures 2, 3 and 4 for electrical, 
thermal and mechanical thresholds, respectively. Treatment DHM resulted in the highest 
thresholds for all the 3 stimuli. Thermal and mechanical cut-out was reached at most time 
points during the DHM infusion. All nociceptive thresholds increased to the greatest degree 
and for the longest duration with DHM compared to the other treatments (electrical and 
thermal for 135 minutes and mechanical for 150 minutes). Treatments DH and DLM 
provided similar antinociception.  
 
Abdominal auscultation, cardiovascular, and respiratory function 
Differences within and between treatments for abdominal auscultation are shown in Figure 5. 
Intestinal motility was reduced for up to 135 minutes after DL, 150 minutes after DLM and 
210 minutes after DH and DHM.  
 Throughout the study period, cardiovascular function was maintained well within 
acceptable limits in all horses undergoing all treatments (Table 2), with no differences from 
baseline and between treatments for HR, and only one single difference at one time point 
from baseline for SAP. All treatments decreased the fR. This reduction persisted after the end 
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of the infusion significantly for 60 minutes in DL and DH groups and 90 minutes in DLM 
and DHM groups. 
 
Discussion 
The results of this study indicate that the higher detomidine dose combined with methadone 
(DHM) produced the most intense and persistent antinociceptive effects of all the protocols 
for the three stimuli. Sedation and effects on gastrointestinal motility were similar to the high 
dose of detomidine without methadone (DH). Low doses of detomidine with or without 
methadone (DLM and DL) produced less antinociception and sedation but still reduced 
gastrointestinal motility for the duration of the infusion, although scores returned to baseline 
sooner than for DH and DHM. Minimal cardiovascular and respiratory effects were observed 
for all the treatments.  
Treatment DHM produced the most intense antinociceptive effects and these were 
maintained during the 120-minute infusion period. The low dose of detomidine (DL) did not 
produce any antinociception as described previously [13,16,17]. However, when combined 
with methadone (DLM), antinociception was mild and similar to that observed with the high 
dose of detomidine alone (DH). This may be explained by the different effects of the 
interaction of methadone on the effect of detomidine, which were of positive potentiation for 
the electrical and thermal stimuli and from synergistic to additive for the thermal stimulus 
[15].  
 Sedation, indicated by more than or equal to a 50% reduction in HHAG, was similar 
to that observed after a 5 µg/kg bwt bolus of detomidine [13], and described as ‘sufficient’ 
sedation [5]. According to this criterion, overall, only horses treated with the high dose of 
detomidine (DH and DHM) were ‘sufficiently’ sedated. In contrast, low doses of detomidine, 
regardless of the inclusion of methadone (DL and DLM), produced insufficient sedation. This 
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is important if these protocols are to be used in horses undergoing standing surgery when an 
adequate degree of sedation is essential. When using treatment DHM, a certain degree of 
ataxia must be anticipated, with a reduction in the responses to stimuli. Treatments using 2.5 
µg/kg bwt of detomidine appear unlikely to provide adequate sedation for the invasive 
procedures.  
 All treatments reduced gastrointestinal motility. The higher doses of detomidine (DH 
and DHM) produced the greatest effects and for the longest period after the end of the 
infusion. Similar results were also observed when these drugs were given as boli [13], and by 
simulation based on PK/PD models [15]. Although no signs of colic were observed, the 
reduction in motility scores suggests that horses would benefit from close monitoring during 
the first 12 – 24 hours after treatment.  
Detomidine at 5 µg/kg bwt with 0.2 mg/kg bwt of methadone also provided 
antinociception with adequate sedation in a previous report [13]. For prolonged maintenance 
of sedation and antinociception, the 12.5 µg/kg bwt/h rate for detomidine co-administered 
with methadone (DHM) appeared to be the best of all the treatments. When given alone, 
detomidine infusion rates of around 9 µg/kg bwt/h were successfully used for laparoscopy 
[8,9], whereas rates of approximately 20 µg/kg bwt/h were required for dental or sinus 
procedures [10,11]. Clinical studies are needed to determine if the DHM protocol might be 
useful, or if the rate should be adapted to different surgical procedures.  
Methadone was used to enhance the sedative properties of detomidine, provide 
analgesia [24], and reduce the dose and infusion rate of the α2-agonist. To date, the use of 
methadone as a co-infusion with an α2-agonist has not been reported in horses. Excitatory 
effects, such as head-shaking, linked to the use of 0.2 mg/kg bwt of methadone [16] may 
occur, especially when using low doses of detomidine. In the current study, only one horse 
showed mild head-shaking in response to external stimuli after the bolus in treatment DLM. 
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A low dose of 2.5 µg/kg bwt may not always overcome the potential excitatory effects of 
opioids. The κ- agonist, butorphanol, is the opioid most widely studied for use as a CRI [4-7], 
but methadone, a full µ-agonist, might be more appropriate for more painful surgical 
procedures. Two reports suggest that buprenorphine, a partial µ-agonist opioid, when 
combined with detomidine infusion, although contributing to antinociception, may lead to 
abdominal pain and increase locomotor activity [10,11]. However, minimal complications 
were observed in a large clinical study of horses sedated with romifidine and buprenorphine 
before elective general anaesthesia [25]. 
 Most equine standing sedation protocols are based on clinical experience, 
experimental [3-9], clinical [10,11] or retrospective [12] studies. Our study is innovative 
because we used the data from our previous boli study [13] to perform PK/PD modelling 
[14,15]. Recent refinements in sequential PK/PD modelling allow concentration-effect data to 
be determined and the effects on different PD variables to be predicted according to plasma 
concentrations. In our PK/PD study [15], we were able to determine the different interactions 
between both drugs for each PD variable, and even to simulate the effects of different dose 
and rate ranges regarding sedation (HHAG), antinociception and gastrointestinal motility 
[15]. This demonstrates that PK/PD modelling can be used to predict more precisely the 
expected effects of future equine clinical trials.   
The main limitation of our study related to the extrapolation of the results to a clinical 
scenario as: (i) nociceptive stimuli are not real surgical stimuli, even when validated for 
experimental studies in standing horses [20]; (ii) surgical pain in different locations may 
differ in intensity due to specific innervation; and (iii) understanding of the magnitude of 
inter-animal variability is limited from a group of 7 horses. Study of a larger clinical 
population undergoing a range of standing surgical procedures is needed to confirm the 
predicted clinical effects. 
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Conclusions 
In conclusion, the high dose of detomidine combined with methadone produced the most 
potent and persistent antinociception, with minimal adverse effects. This protocol appears 
likely to be useful for clinical surgical procedures and future studies to evaluate its clinical 
applicability are justified. 
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Figure legends 
 
Fig 1: Height of head above the ground (HHAG) in 7 standing horses given i.v. saline (SAL), 
detomidine low (DL) (2.5 µg/kg + 6.25 µg/kg bwt/h) and high doses alone (DH) (5 µg/kg + 
12.5 µg/kg bwt/h) or combined with methadone (0.2 mg/kg + 0.05 mg/kg bwt/h) (DLM and 
DHM) for 120 minutes. Dotted line at T120 indicates the end of infusion. Data are mean ± 
s.d. Significant differences were the following: * Values lower than time 0 within the same 
treatment. † Values after DL, DH, DLM and DHM lower than SAL. ‡ Values after DL, DH 
and DHM lower than SAL. § Values after DH and DHM lower than SAL. α Values after 
DHM lower than DLM. β Values after DH lower than DLM. δ Values after DH lower than 
DL. # Values after DHM lower than DL. (p<0.05). 
 
Fig 2: Electrical [upper safety limit 20 Volts (V)] thresholds in 7 standing horses given i.v. 
saline (SAL), detomidine low (DL) (2.5 µg/kg bwt + 6.25 µg/kg bwt/h) and high doses alone 
(DH) (5 µg/kg bwt + 12.5 µg/kg bwt/h) or combined with methadone (0.2 mg/kg bwt + 0.05 
mg/kg bwt/h) (DLM and DHM) for 120 minutes. Dotted line at T120 indicates the end of 
infusion. Data are mean ± s.d. Significant differences were the following: * Values higher 
than time 0 within the same treatment. † Values after DHM higher than DH, DLM, DL and 
SAL. ‡ Values after DHM higher than DL and SAL. § Values after DH higher than SAL. α 
Values after DLM higher than SAL. (p<0.05). 
 
Fig 3: Thermal [upper safety limit 60 degrees Celsius (°C)] thresholds in 7 standing horses 
given i.v. saline (SAL), detomidine low (DL) (2.5 µg/kg bwt + 6.25 µg/kg bwt/h) and high 
doses alone (DH) (5 µg/kg bwt + 12.5 µg/kg bwt/h) or combined with methadone (0.2 mg/kg 
bwt + 0.05 mg/kg bwt/h) (DLM and DHM) for 120 minutes. Dotted line at T120 indicates the 
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end of infusion. Data are mean ± s.d. Significant differences were the following: * Values 
higher than time 0 within the same treatment. † Values after DHM, DH and DLM higher than 
SAL. ‡ Values after DHM higher than SAL. § Values after DHM higher than DL. α Values 
after DH higher than DL. β Values after DLM higher than DL. (p<0.05). 
 
Fig 4: Mechanical [upper safety limit 20 Newtons (N)] thresholds in 7 standing horses given 
i.v. saline (SAL), detomidine low (DL) (2.5 µg/kg bwt + 6.25 µg/kg bwt/h) and high doses 
alone (DH) (5 µg/kg bwt + 12.5 µg/kg bwt/h) or combined with methadone (0.2 mg/kg bwt + 
0.05 mg/kg bwt/h) (DLM and DHM) for 120 minutes. Dotted line at T120 indicates the end 
of infusion. Data are mean ± s.d. Significant differences were the following: * Values higher 
than time 0 within the same treatment. † Values after DHM higher than DL and SAL. ‡ 
Values after DHM higher than DH. § Values after DHM higher than DLM. α Values after 
DH and DLM higher than SAL. β Values after DH higher than DL. δ Values after DLM 
higher than SAL. # Values after DLM higher than DL. (p<0.05). 
 
Fig 5: Intestinal motility in 7 standing horses given i.v. saline (SAL), detomidine low (DL) 
(2.5 µg/kg + 6.25 µg/kg bwt/h) and high doses alone (DH) (5 µg/kg + 12.5 µg/kg bwt/h) or 
combined with methadone (0.2 mg/kg + 0.05 mg/kg bwt/h) (DLM and DHM) for 120 
minutes. Dotted line at T120 indicates the end of infusion. Data are mean ± s.d. Significant 
differences were the following: * Values lower than time 0 within the same treatment. † 
Scores after SAL higher than DL, DLM, DH and DHM. ‡ Scores after SAL higher than DH 
and DHM. α Scores after DL higher than DH. β Scores after DL higher than DHM. § Scores 
after DL and DLM higher than DHM. # Scores after DLM higher than DH. (p<0.05). 
Supporting Information 
Supplementary Item 1: Numerical rating scales.  
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Table 1: Ataxia scores in 7 standing horses administered intravenous saline intravenously 
(SAL), detomidine low (DL) (2.5 µg/kg bwt + 6.25 µg/kg bwt/h) and high doses alone (DH) 
(5 µg/kg bwt + 12.5 µg/kg bwt/h) or combined with methadone (0.2 mg/kg bwt + 0.05 mg/kg 
bwt/h) (DLM and DHM) for 120 minutes. Data are presented in [median (range)], where 0 
indicates, no ataxia and 3 indicates severe ataxia sedation and ataxia (Supplementary Item 1). 
 
Variable Time (minutes) Treatments
SAL DL DH DLM DHM 
Ataxia 0 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 
5 0 (0 - 0) 0 (0 - 1) 0.5 (0 - 2) 0 (0 - 1) 0.5 (0 - 3) 
15 0 (0 - 1)a 0 (0 - 1)a  1 (0 - 3)ab 0 (0 - 1)ab 2 (1 - 3)b 
30 0 (0 - 0)a 1 (0 - 2)ab 1 (0 - 2)ab 1 (0 - 1)ab 2 (1 - 3)*b 
60 0 (0 - 0)a 1 (0 - 2)ab 1 (0 - 2) ab 1 (0 - 2)ab 2.5 (1 - 3)*b 
90 0 (0 - 0)a 1 (0 - 2)ab 1 (0 - 2)ab 0.5 (0 - 2)ab 1.5 (1 - 3)b 
120 0 (0 - 0)a 0.5 (0 - 1)ab  1 (0 - 3) ab 1 (0 - 2)ab 2 (1 - 3)b 
135 0 (0 - 0) 0 (0 - 2) 0.5 (0 - 3) 0.5 (0 - 1) 1.5 (0 - 3)  
150 0 (0 - 0) 0 (0 - 1) 0 (0 - 3) 0 (0 - 0) 1 (0 - 2) 
180 0 (0 - 0) 0 (0 - 0) 0 (0 - 2) 0 (0 - 0) 0 (0 - 1) 
210 0 (0 - 0) 0 (0 - 0) 0 (0 - 1) 0 (0 - 0) 0 (0 - 1) 
240 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 0 (0 - 0) 
 
*Significantly different from baseline (time 0) within a treatment (p<0.05).  
abc
 Different superscript letters indicate significant differences between treatments at that time point 
(p<0.05). Dotted line at T120 indicates the end of infusion. 
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Table 2: Heart rate (HR), systolic arterial blood pressure (SAP) and respiratory rate (fR) (mean ± s.d.) 
in 7 standing horses administered i.v. saline (SAL), detomidine low (DL) (2.5 µg/kg bwt + 6.25 µg/kg 
bwt/h) and high doses alone (DH) (5 µg/kg bwt + 12.5 µg/kg bwt/h) or combined with methadone 
(0.2 mg/kg bwt + 0.05 mg/kg bwt/h) (DLM and DHM) for 120 minutes. Data are presented as mean ± 
s.d. 
 
Variable Time (minutes) Treatment
SAL DL DH DLM DHM 
HR (bpm) 0 46 ± 7   43 ± 4 46 ± 6 47 ± 7 44 ± 7  
5 48 ± 11 41 ± 7 42 ± 9 45 ± 12 39 ± 8 
15 47 ± 9 42 ± 5 37 ± 5 44 ± 12 41 ± 13 
30 46 ± 10 41 ± 6 41 ± 11 43 ± 13 37 ± 11 
60 45 ±10 41 ± 6 41 ± 13 44 ± 15 40 ± 12  
90 44 ± 9 41 ± 6 40 ± 8 44 ± 17 41 ± 12 
120 45 ± 10 41 ± 8 41 ± 9 45 ± 17 41 ± 14 
135 46 ± 10 43 ± 8 42 ± 7 44 ± 8 42 ± 12 
150 45 ± 12 43 ± 7 43 ± 6 43 ± 12 43 ± 12 
180 46 ± 12 47 ± 9 44 ± 10 47 ± 13 47 ± 13 
210 47 ± 13 43 ± 6 45 ± 9 46 ± 14 46 ± 13 
240 45 ± 11 41 ± 6 45 ± 9 44 ± 12 46 ± 14 
SAP (mmHg) 0 141 ± 12 137 ± 10 140 ± 15 143 ± 12 136 ± 9 
5 130 ± 9 130 ± 10 148 ± 16 149 ± 13 136 ± 14 
15 135 ± 14 123 ± 9 144 ± 12 139 ± 20 138 ± 21 
30 130 ± 14 125 ± 9 144 ± 21 139 ± 22 142 ± 19 
60 135 ± 16 124 ± 11 142 ± 18 132 ± 14 141 ± 19 
90 131 ± 11 137 ± 12 136 ± 17 129 ± 15 142 ± 16 
120 134 ± 17 130 ± 14 130 ± 15 125 ± 10 131 ± 14 
135 131 ± 17 124 ± 11 123 ± 10 111 ± 9* 120 ± 11 
150 139 ± 19 116 ± 8 116 ± 7 121 ± 11 119 ± 10 
180 138 ± 14 121 ± 10 114 ± 8 130 ± 16 116 ± 6 
210 133 ± 14 130 ± 12 118 ± 12 135 ± 11 119 ± 5 
240 135 ± 12 122 ± 10 122 ± 12 138 ± 11 121 ± 11 
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fR (rpm) 0 19 ± 3 20 ± 3 18 ± 2 20 ± 3 18 ± 3 
5 20 ± 4a 16 ± 3ab 13 ± 4b 15 ± 5ab 11 ± 2*b 
15 19 ± 4a 16 ± 4ab 11 ± 1*bc 16 ± 5ab 9 ± 1*c 
30 19 ± 4a 14 ± 3*b 10 ± 2*bc 14 ± 3*b 8 ± 1*c 
60 19 ± 2a 12 ± 3*b 10 ± 2*b 11 ± 2*b 9 ± 2*b 
90 20 ± 1a 11 ± 3*b 10 ± 2*b 12 ± 2*b 8 ± 1*b 
120 21 ± 2a 10 ± 3*b 9 ± 2*b 10 ± 2*b 9 ± 1*b 
135 19 ± 1a 12 ± 2*b 9 ± 2*b 10 ± 1*b 9 ± 1*b 
150 18 ± 2a 12 ± 2*b 10 ± 2*b 12 ± 2*b 10 ± 2*b 
180 20 ± 2a 15 ± 2*ab 12 ± 3*b 14 ± 3*b 10 ± 2*b 
210 19 ±2a 16 ± 1ab 13 ± 3b 15 ± 5*ab 11 ± 2*b 
240 20 ± 2a 16 ± 2ab 14 ± 3b 16 ± 2ab 14 ± 3b 
 
*Significantly different from baseline (time 0) within a treatment (p<0.05).  
abc
 Different superscript letters indicate significant differences between treatments at that time point 
(p<0.05). Dotted line at T120 indicates the end of infusion.  
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